## **Gregory L Stahl**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4696445/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predominant role for C5b-9 in renal ischemia/reperfusion injury. Journal of Clinical Investigation, 2000, 105, 1363-1371.	8.2	418
2	Human IgA Activates the Complement System Via the Mannan-Binding Lectin Pathway. Journal of Immunology, 2001, 167, 2861-2868.	0.8	385
3	Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion. Circulation, 1998, 97, 2259-2267.	1.6	382
4	Reduced Inflammation and Tissue Damage in Transgenic Rabbits Overexpressing 15-Lipoxygenase and Endogenous Anti-inflammatory Lipid Mediators. Journal of Immunology, 2003, 171, 6856-6865.	0.8	364
5	Glomerular Activation of the Lectin Pathway of Complement in IgA Nephropathy Is Associated with More Severe Renal Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 1724-1734.	6.1	357
6	Complement Activation after Oxidative Stress. American Journal of Pathology, 2000, 156, 1549-1556.	3.8	314
7	Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. Circulation, 1999, 100, 2499-2506.	1.6	282
8	Inhibition of Mannose-Binding Lectin Reduces Postischemic Myocardial Reperfusion Injury. Circulation, 2001, 104, 1413-1418.	1.6	240
9	Mannose-Binding Lectin Is a Regulator of Inflammation That Accompanies Myocardial Ischemia and Reperfusion Injury. Journal of Immunology, 2005, 175, 541-546.	0.8	226
10	Complement Induction in Spinal Cord Microglia Results in Anaphylatoxin C5a-Mediated Pain Hypersensitivity. Journal of Neuroscience, 2007, 27, 8699-8708.	3.6	211
11	Neutrophil-derived 5′-Adenosine Monophosphate Promotes Endothelial Barrier Function via CD73-mediated Conversion to Adenosine and Endothelial A2B Receptor Activation. Journal of Experimental Medicine, 1998, 188, 1433-1443.	8.5	210
12	Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated Hemoglobin in Pigs. Circulation, 1999, 99, 2302-2309.	1.6	185
13	Gastrointestinal Ischemia-Reperfusion Injury Is Lectin Complement Pathway Dependent without Involving C1q. Journal of Immunology, 2005, 174, 6373-6380.	0.8	183
14	Polyglycolic Acid-Induced Inflammation: Role of Hydrolysis and Resulting Complement Activation. Tissue Engineering, 2006, 12, 301-308.	4.6	161
15	Neutrophil-derived Glutamate Regulates Vascular Endothelial Barrier Function. Journal of Biological Chemistry, 2002, 277, 14801-14811.	3.4	155
16	Role for the Alternative Complement Pathway in Ischemia/Reperfusion Injury. American Journal of Pathology, 2003, 162, 449-455.	3.8	151
17	Role for Periodontitis in the Progression of Lipid Deposition in an Animal Model. Infection and Immunity, 2003, 71, 6012-6018.	2.2	150
18	The Lectin Pathway of Complement Activation Is a Critical Component of the Innate Immune Response to Pneumococcal Infection. PLoS Pathogens, 2012, 8, e1002793.	4.7	144

#	Article	IF	CITATIONS
19	ROLE OF THE ALTERNATIVE PATHWAY IN THE EARLY COMPLEMENT ACTIVATION FOLLOWING MAJOR TRAUMA. Shock, 2007, 28, 29-34.	2.1	138
20	Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury. Journal of Thoracic and Cardiovascular Surgery, 2009, 138, 977-984.	0.8	135
21	Role of C3a Receptors, C5a Receptors, and Complement Protein C6 Deficiency in Collagen Antibody-Induced Arthritis in Mice. Journal of Immunology, 2012, 188, 1469-1478.	0.8	122
22	Targeting Mannose-Binding Lectin Confers Long-Lasting Protection With a Surprisingly Wide Therapeutic Window in Cerebral Ischemia. Circulation, 2012, 126, 1484-1494.	1.6	119
23	Endothelial Oxidative Stress Activates the Lectin Complement Pathway. American Journal of Pathology, 2001, 159, 1045-1054.	3.8	118
24	The complement system in ischemia–reperfusion injuries. Immunobiology, 2012, 217, 1026-1033.	1.9	118
25	Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology, 2006, 211, 759-766.	1.9	101
26	Identification of a Cytochrome P4502E1/Bid/C1q-dependent Axis Mediating Inflammation in Adipose Tissue after Chronic Ethanol Feeding to Mice. Journal of Biological Chemistry, 2011, 286, 35989-35997.	3.4	96
27	Hypoxia enhances induction of endothelial ICAM-1: role for metabolic acidosis and proteasomes. American Journal of Physiology - Cell Physiology, 1997, 273, C1571-C1580.	4.6	94
28	Role of extracellular nucleotide phosphohydrolysis in intestinal ischemiaâ€reperfusion injury. FASEB Journal, 2008, 22, 2784-2797.	0.5	89
29	Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12282-12287.	7.1	88
30	Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1853-H1859.	3.2	88
31	The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Molecular Immunology, 2009, 47, 373-380.	2.2	83
32	Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology, 2011, 216, 96-102.	1.9	82
33	Mannose-Binding Lectin-Associated Serine Protease-1 Is a Significant Contributor to Coagulation in a Murine Model of Occlusive Thrombosis. Journal of Immunology, 2012, 188, 885-891.	0.8	79
34	Reoxygenation of Hypoxic Human Umbilical Vein Endothelial Cells Activates the Classic Complement Pathway. Circulation, 1997, 96, 326-333.	1.6	79
35	The Alternative Complement Pathway Propagates Inflammation and Injury in Murine Ischemic Stroke. Journal of Immunology, 2012, 189, 4640-4647.	0.8	78
36	Endogenous and Natural Complement Inhibitor Attenuates Myocardial Injury and Arterial Thrombogenesis. Circulation, 2012, 126, 2227-2235.	1.6	74

#	Article	IF	CITATIONS
37	Antiadhesive Role of Apical Decay-accelerating Factor (CD55) in Human Neutrophil Transmigration across Mucosal Epithelia. Journal of Experimental Medicine, 2003, 198, 999-1010.	8.5	73
38	Targeted Inhibition of the Complement Alternative Pathway with Complement Receptor 2 and Factor H Attenuates Collagen Antibody-Induced Arthritis in Mice. Journal of Immunology, 2009, 183, 5928-5937.	0.8	68
39	Lectin-Dependent Enhancement of Ebola Virus Infection via Soluble and Transmembrane C-type Lectin Receptors. PLoS ONE, 2013, 8, e60838.	2.5	67
40	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. Molecular Therapy, 2015, 23, 1066-1076.	8.2	65
41	Complement-Mediated Loss of Endothelium-Dependent Relaxation of Porcine Coronary Arteries. Circulation Research, 1995, 76, 575-583.	4.5	63
42	A Stable Aspirin-Triggered Lipoxin A4 Analog Blocks Phosphorylation of Leukocyte-Specific Protein 1 in Human Neutrophils. Journal of Immunology, 2004, 173, 2091-2098.	0.8	60
43	Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. Journal of Thoracic and Cardiovascular Surgery, 1998, 116, 1060-1068.	0.8	59
44	Direct Treatment of Mouse or Human Blood With Soluble 5′-Nucleotidase Inhibits Platelet Aggregation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1477-1483.	2.4	59
45	Initiation of complement activation following oxidative stress.In vitro and in vivo observations. Molecular Immunology, 2004, 41, 165-171.	2.2	58
46	Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. Journal of Clinical Investigation, 2005, 115, 1590-1600.	8.2	58
47	Murine model of gastrointestinal ischemia associated with complement-dependent injury. Journal of Applied Physiology, 2002, 93, 338-345.	2.5	57
48	Mesenteric dysfunction after cardiopulmonary bypass: role of complement C5a. Annals of Thoracic Surgery, 2000, 69, 799-807.	1.3	55
49	Reduced Tissue Damage and Improved Recovery of Motor Function after Traumatic Brain Injury in Mice Deficient in Complement Component C4. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1954-1964.	4.3	55
50	Essential Role of Complement Mannose-Binding Lectin-Associated Serine Proteases-1/3 in the Murine Collagen Antibody-Induced Model of Inflammatory Arthritis. Journal of Immunology, 2010, 185, 5598-5606.	0.8	55
51	Complement activation following reoxygenation of hypoxic human endothelial cells: Role of intracellular reactive oxygen species, NF-IºB and new protein synthesis. Immunopharmacology, 1998, 39, 39-50.	2.0	54
52	The alternative complement pathway regulates pathological angiogenesis in the retina. FASEB Journal, 2014, 28, 3171-3182.	0.5	54
53	Mannose Binding Lectin Gene Deficiency Increases Susceptibility to Traumatic Brain Injury in Mice. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1030-1039.	4.3	52
54	A Novel L-ficolin/Mannose-binding Lectin Chimeric Molecule with Enhanced Activity against Ebola Virus. Journal of Biological Chemistry, 2010, 285, 24729-24739.	3.4	51

#	Article	IF	CITATIONS
55	Endothelial Nuclear Factor-κB Translocation and Vascular Cell Adhesion Molecule-1 Induction by Complement. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2623-2629.	2.4	50
56	Therapeutic potential of targeting the complement cascade in critical care medicine. Critical Care Medicine, 2003, 31, S97-S104.	0.9	47
57	Role of complement component C5 in cerebral ischemia/reperfusion injury. Brain Research, 2006, 1100, 142-151.	2.2	46
58	Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. American Journal of Physiology - Cell Physiology, 1999, 276, C450-C458.	4.6	45
59	Essential Role of Factor B of the Alternative Complement Pathway in Complement Activation and Opsonophagocytosis during Acute Pneumococcal Otitis Media in Mice. Infection and Immunity, 2011, 79, 2578-2585.	2.2	40
60	A Keratin Peptide Inhibits Mannose-Binding Lectin. Journal of Immunology, 2001, 166, 4148-4153.	0.8	38
61	The Role of Properdin in Zymosan- and <i>Escherichia coli</i> -Induced Complement Activation. Journal of Immunology, 2012, 189, 2606-2613.	0.8	38
62	CpG Oligodeoxynucleotide Protection in Polymicrobial Sepsis Is Dependent on Interleukinâ€17. Journal of Infectious Diseases, 2005, 191, 1368-1376.	4.0	36
63	Cholesterol Crystals Activate the Lectin Complement Pathway via Ficolin-2 and Mannose-Binding Lectin: Implications for the Progression of Atherosclerosis. Journal of Immunology, 2016, 196, 5064-5074.	0.8	35
64	Humanized cobra venom factor decreases myocardial ischemia–reperfusion injury. Molecular Immunology, 2009, 47, 506-510.	2.2	33
65	Molecular basis for complement component 6 (C6) deficiency in rats and mice. Immunobiology, 2004, 209, 559-568.	1.9	32
66	Inhibition of C5 or absence of C6 protects from sepsis mortality. Immunobiology, 2004, 209, 629-635.	1.9	32
67	Human mannose-binding lectin inhibitor prevents Shiga toxin–induced renal injury. Kidney International, 2016, 90, 774-782.	5.2	31
68	Complement Activation and Cardiac Surgery. Anesthesia and Analgesia, 2012, 115, 759-771.	2.2	29
69	Human Mannose-Binding Lectin Inhibitor Prevents Myocardial Injury and Arterial Thrombogenesis in a Novel Animal Model. American Journal of Pathology, 2015, 185, 347-355.	3.8	29
70	The Contribution of Mannose Binding Lectin to Reperfusion Injury after Ischemic Stroke. Current Neurovascular Research, 2011, 8, 52-63.	1.1	28
71	In Vivo and In Vitro Assessment of Porcine Neutrophil Activation Responses to Chemoattractants: Flow Cytometric Evidence for the Selective Absence of Formyl Peptide Receptors. Journal of Leukocyte Biology, 1990, 47, 355-365.	3.3	27
72	Distinct Different Contributions of the Alternative and Classical Complement Activation Pathway for the Innate Host Response during Sepsis. Journal of Immunology, 2011, 186, 3066-3075.	0.8	27

#	Article	IF	CITATIONS
73	PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart. Naunyn-Schmiedeberg's Archives of Pharmacology, 1987, 336, 459-463.	3.0	26
74	Identification of Human Mannose Binding Lectin (MBL) Recognition Sites for Novel Inhibitory Antibodies. Hybridoma, 2002, 21, 25-36.	0.4	26
75	Enhanced Susceptibility to Acute Pneumococcal Otitis Media in Mice Deficient in Complement C1qa, Factor B, and Factor B/C2. Infection and Immunity, 2010, 78, 976-983.	2.2	26
76	Roles of Adipocytes and Fibroblasts in Activation of the Alternative Pathway of Complement in Inflammatory Arthritis in Mice. Journal of Immunology, 2013, 190, 6423-6433.	0.8	25
77	Genetic ablation or chemical inhibition of phosphatidylcholine transfer protein attenuates diet-induced hepatic glucose production. Hepatology, 2011, 54, 664-674.	7.3	24
78	Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. Thrombosis Research, 1989, 53, 327-338.	1.7	23
79	Attenuation of Endothelium-Dependent Dilation of Pig Pulmonary Arterioles After Cardiopulmonary Bypass Is Prevented by Monoclonal Antibody to Complement C5a. Anesthesia and Analgesia, 1999, 89, 42-48.	2.2	23
80	Complement 3 is involved with ventilator-induced lung injury. International Immunopharmacology, 2011, 11, 2138-2143.	3.8	23
81	Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. Molecular Immunology, 2011, 49, 281-289.	2.2	23
82	Absence of Mannose-Binding Lectin Prevents Hyperglycemic Cardiovascular Complications. American Journal of Pathology, 2012, 180, 104-112.	3.8	23
83	Complementary Roles of the Classical and Lectin Complement Pathways in the Defense against Aspergillus fumigatus. Frontiers in Immunology, 2016, 7, 473.	4.8	23
84	Protective Effects of a Platelet Activating Factor (PAF) Antagonist and Its Combined Treatment with Prostaglandin (PG) E1 in Traumatic Shock. Journal of Cardiovascular Pharmacology, 1988, 12, 505-511.	1.9	20
85	The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart. Diabetes and Vascular Disease Research, 2009, 6, 172-180.	2.0	19
86	Deletion of the Complement C5a Receptor Alleviates the Severity of Acute Pneumococcal Otitis Media following Influenza A Virus Infection in Mice. PLoS ONE, 2014, 9, e95160.	2,5	18
87	Complement depletion with humanised cobra venom factor: Efficacy in preclinical models of vascular diseases. Thrombosis and Haemostasis, 2015, 113, 548-552.	3.4	18
88	C5-blocking antibody reduces fluid requirements and improves responsiveness to fluid infusion in hemorrhagic shock managed with hypotensive resuscitation. Journal of Applied Physiology, 2007, 102, 673-680.	2.5	17
89	Coronary Vascular Actions of Synthetic Atrial Natriuretic Factor in Isolated Vascular Preparations. Journal of Cardiovascular Pharmacology, 1987, 10, 320-326.	1.9	14
90	Role of the alternative and classical complement activation pathway in complement mediated killing against Streptococcus pneumoniae colony opacity variants during acute pneumococcal otitis media in mice. Microbes and Infection, 2012, 14, 1308-1318.	1.9	14

#	Article	IF	CITATIONS
91	Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Advances in Experimental Medicine and Biology, 2008, 632, 293-307.	1.6	14
92	Ulex europaeusagglutinin II (UEA-II) is a novel, potent inhibitor of complement activation. Protein Science, 2001, 10, 277-284.	7.6	13
93	Anoxia and reoxygenation of human endothelial cells decreases ceramide glucosyltransferase expression and activates caspases. FASEB Journal, 2003, 17, 723-724.	0.5	13
94	Fluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage. Journal of Immunological Methods, 2007, 323, 147-159.	1.4	12
95	Isolation, Characterization, and Cloning of Porcine Complement Component C7. Journal of Immunology, 2000, 165, 1059-1065.	0.8	10
96	Efficacy of a combination thromboxane receptor antagonist and lipoxygenase inhibitor in traumatic shock. Resuscitation, 1988, 16, 211-220.	3.0	8
97	Protective action of prostaglandin E1 (PGE1) against constrictor mediators in isolated rat heart and lung. Biochemical Pharmacology, 1988, 37, 2659-2665.	4.4	8
98	Effect of sialyl Lewisx oligosaccharide on myocardial and cerebral injury in the pig. Annals of Thoracic Surgery, 1999, 67, 112-119.	1.3	8
99	Antagonism of thromboxane actions in the isolated perfused rat heart. Life Sciences, 1986, 38, 2037-2041.	4.3	7
100	Mechanisms of action of PGE1 in hemorrhagic shock in rats. Annals of Emergency Medicine, 1988, 17, 457-462.	0.6	6
101	Inosine Monophosphate and Aspirin-Triggered 15-Epi-Lipoxin A4 Act in Concert to Regulate Neutrophil Trafficking: Additive Actions of Two New Endogenous Anti-Inflammatory Mediators. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 75-79.	1.8	6
102	Heterogeneity of Vascular Smooth Muscle Responsiveness to Lipid Vasoactive Mediators. Journal of Vascular Research, 1987, 24, 24-30.	1.4	5
103	Protective effects f CG-4203, a novel stable prostacyclin analog, in traumatic shock. Prostaglandins, 1988, 35, 41-50.	1.2	5
104	Mechanisms of the Hepatoprotective Effect of Nitrendipine in the Isolated Perfused Cat Liver. Journal of Cardiovascular Pharmacology, 1987, 9, S66-S70.	1.9	4
105	Mannose-binding lectin (MBL) and the lectin complement pathway play a role in cutaneous ischemia and reperfusion injury. Innovative Surgical Sciences, 2020, 5, 43-51.	0.7	2
106	Complement Deposition is Increased in the Type 2 Diabetic Heart Following Ischemia/Reperfusion. FASEB Journal, 2007, 21, A1225.	0.5	0
107	C1 inhibitor regulates the activation of the mannose binding lectinâ€dependent lectin pathway following ischemiaâ€reperfusion. FASEB Journal, 2007, 21, A1145.	0.5	0
108	Increased mRNA Expression of Endothelial Adhesion Molecules and Proinflammatory Cytokines in the Type 2 Diabetic Heart Following Ischemia/Reperfusion Injury. FASEB Journal, 2007, 21, A1145.	0.5	0

#	Article	IF	CITATIONS
109	Mannose binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. FASEB Journal, 2007, 21, A1144.	0.5	0
110	Complement Gene Expression is Upregulated in the Type 2 Diabetic Heart Following Myocardial Ischemia and Reperfusion. FASEB Journal, 2007, 21, A1224.	0.5	0
111	Increased susceptibility to myocardial ischemia and reperfusion injury in type I diabetes mellitus is mannoseâ€binding lectin dependent. FASEB Journal, 2007, 21, A11.	0.5	Ο
112	Role of the mouse complement components C5 and C3a in a model of myocardial ischemia and reperfusion injury. FASEB Journal, 2007, 21, A12.	0.5	0
113	Inhibition of Mannoseâ€Binding Lectin Decreases Infarction Size After Ischemic Stroke and Reperfusion. FASEB Journal, 2008, 22, 733.2.	0.5	Ο
114	Treatment with the complement inhibitor, FUTâ€175 decreases PMN activation and myocardial infarct size in Spragueâ€Dawley rats. FASEB Journal, 2008, 22, 730.29.	0.5	0
115	Neutrophil expression of the C5a receptor is increased in type 2 diabetes. FASEB Journal, 2008, 22, 48.11.	0.5	Ο
116	The MBLâ€complex is necessary for FeCl3â€mediated thrombosis. FASEB Journal, 2010, 24, 1028.5.	0.5	0
117	MBLâ€associated serine protease 1 (MASPâ€1) is necessary for thrombin substrate cleavage in vitro. FASEB Journal, 2010, 24, 951.15.	0.5	Ο
118	Mannoseâ€binding lectin concentrations correlate with enhanced whole blood aggregation and thrombinâ€like activity in humans. FASEB Journal, 2012, 26, .	0.5	0
119	Human Mannoseâ€Binding Lectin (MBL2) Inhibitor Prevents Renal Injury in a Novel Animal Model of	0.5	0